Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 5/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 3/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831486 | 0.93 | CYP2C8 (0.47) | CYP2C8GNRHRKMT2AMEN1PPARG | |
| SCHEMBL832103 | 0.89 | CYP2C8 (0.43) | CYP2C8GNRHRKMT2AMEN1PPARG | |
| SCHEMBL831233 | 0.87 | CYP2C8 (0.42) | CYP2C8KMT2AMEN1PTGDR2CYP2C9 | |
| SCHEMBL12673670 | 0.86 | CYP2C8 (0.57) | CYP2C8GNRHRKMT2AMEN1PTGDR2 | |
| SCHEMBL831476 | 0.84 | CYP2C8 (0.39) | CYP2C8KMT2AMEN1PTGDR2PPARG | |
| SCHEMBL831531 | 0.84 | CYP2C8 (0.48) | CYP2C8GNRHRKMT2AMEN1PPARG | |
| SCHEMBL830778 | 0.83 | CYP2C8 (0.54) | CYP2C8KMT2AMEN1PTGDR2PPARG | |
| SCHEMBL831710 | 0.83 | CYP2C8 (0.43) | CYP2C8KMT2AMEN1PTGDR2CYP2C9 | |
| SCHEMBL831116 | 0.83 | CYP2C8 (0.49) | CYP2C8KMT2AMEN1PPARG | |
| SCHEMBL831258 | 0.83 | CYP2C8 (0.53) | CYP2C8KMT2AMEN1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885GNRHR 3611/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.